Retina Oculomics in Neurodegenerative Disease.
Machine learning
Oculomics
Retina
Systemic disease
Journal
Annals of biomedical engineering
ISSN: 1573-9686
Titre abrégé: Ann Biomed Eng
Pays: United States
ID NLM: 0361512
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
07
2023
accepted:
05
09
2023
medline:
9
11
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
ppublish
Résumé
Ophthalmic biomarkers have long played a critical role in diagnosing and managing ocular diseases. Oculomics has emerged as a field that utilizes ocular imaging biomarkers to provide insights into systemic diseases. Advances in diagnostic and imaging technologies including electroretinography, optical coherence tomography (OCT), confocal scanning laser ophthalmoscopy, fluorescence lifetime imaging ophthalmoscopy, and OCT angiography have revolutionized the ability to understand systemic diseases and even detect them earlier than clinical manifestations for earlier intervention. With the advent of increasingly large ophthalmic imaging datasets, machine learning models can be integrated into these ocular imaging biomarkers to provide further insights and prognostic predictions of neurodegenerative disease. In this manuscript, we review the use of ophthalmic imaging to provide insights into neurodegenerative diseases including Alzheimer Disease, Parkinson Disease, Amyotrophic Lateral Sclerosis, and Huntington Disease. We discuss recent advances in ophthalmic technology including eye-tracking technology and integration of artificial intelligence techniques to further provide insights into these neurodegenerative diseases. Ultimately, oculomics opens the opportunity to detect and monitor systemic diseases at a higher acuity. Thus, earlier detection of systemic diseases may allow for timely intervention for improving the quality of life in patients with neurodegenerative disease.
Identifiants
pubmed: 37855949
doi: 10.1007/s10439-023-03365-0
pii: 10.1007/s10439-023-03365-0
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2708-2721Subventions
Organisme : NASA Grant
ID : 80NSSC20K183
Informations de copyright
© 2023. The Author(s) under exclusive licence to Biomedical Engineering Society.
Références
London, A., I. Benhar, and M. Schwartz. The retina as a window to the brain—from eye research to CNS disorders. Nat. Rev. Neurol. 9(1):44–53, 2013. https://doi.org/10.1038/nrneurol.2012.227 .
doi: 10.1038/nrneurol.2012.227
Wagner, S. K., D. J. Fu, L. Faes, et al. Insights into systemic disease through retinal imaging-based oculomics. Transl. Vis. Sci. Technol. 9(2):6, 2020. https://doi.org/10.1167/tvst.9.2.6 .
doi: 10.1167/tvst.9.2.6
pmcid: 7343674
Moreno-Ramos, T., J. Benito-Leon, A. Villarejo, and F. Bermejo-Pareja. Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease. J. Alzheimers Dis. 34(3):659–664, 2013. https://doi.org/10.3233/JAD-121975 .
doi: 10.3233/JAD-121975
Jo, T., K. Nho, and A. J. Saykin. Deep learning in Alzheimer’s disease: diagnostic classification and prognostic prediction using neuroimaging data. Front. Aging Neurosci. 11:220, 2019. https://doi.org/10.3389/fnagi.2019.00220 .
doi: 10.3389/fnagi.2019.00220
pmcid: 6710444
Majeed, A., B. Marwick, H. Yu, H. Fadavi, and M. Tavakoli. Ophthalmic biomarkers for Alzheimer’s disease: a review. Front. Aging Neurosci. 13:720167, 2021. https://doi.org/10.3389/fnagi.2021.720167 .
doi: 10.3389/fnagi.2021.720167
pmcid: 8461312
Ukalovic, K., S. Cao, S. Lee, et al. Drusen in the peripheral retina of the Alzheimer’s eye. Curr. Alzheimer Res. 15(8):743–750, 2018. https://doi.org/10.2174/1567205015666180123122637 .
doi: 10.2174/1567205015666180123122637
Chalkias, I. N., T. Tegos, F. Topouzis, and M. Tsolaki. Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders. Eur. J. Ophthalmol. 31(6):2808–2817, 2021. https://doi.org/10.1177/11206721211016311 .
doi: 10.1177/11206721211016311
Huang, D., E. A. Swanson, C. P. Lin, et al. Optical coherence tomography. Science. 254(5035):1178–1181, 1991. https://doi.org/10.1126/science.1957169 .
doi: 10.1126/science.1957169
pmcid: 4638169
Koustenis, A., Jr., A. Harris, J. Gross, I. Januleviciene, A. Shah, and B. Siesky. Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research. Br. J. Ophthalmol. 101(1):16–20, 2017. https://doi.org/10.1136/bjophthalmol-2016-309389 .
doi: 10.1136/bjophthalmol-2016-309389
Macgillivray, T. J., E. Trucco, J. R. Cameron, B. Dhillon, J. G. Houston, and E. J. R. Van Beek. Retinal imaging as a source of biomarkers for diagnosis, characterization and prognosis of chronic illness or long-term conditions. Br. J. Radiol. 87(1040):20130832, 2014. https://doi.org/10.1259/bjr.20130832 .
doi: 10.1259/bjr.20130832
pmcid: 4112401
Schweitzer, D., M. Hammer, F. Schweitzer, et al. In vivo measurement of time-resolved autofluorescence at the human fundus. J. Biomed. Opt. 9(6):1214–1222, 2004. https://doi.org/10.1117/1.1806833 .
doi: 10.1117/1.1806833
Kremers, J., D. J. McKeefry, I. J. Murray, and N. R. A. Parry. Developments in non-invasive visual electrophysiology. Vision Res. 174:50–56, 2020. https://doi.org/10.1016/j.visres.2020.05.003 .
doi: 10.1016/j.visres.2020.05.003
Barnes, D. E., and K. Yaffe. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 10(9):819–828, 2011. https://doi.org/10.1016/S1474-4422(11)70072-2 .
doi: 10.1016/S1474-4422(11)70072-2
pmcid: 3647614
Lim, J. K., Q. X. Li, Z. He, et al. The eye as a biomarker for Alzheimer’s disease. Front Neurosci. 10:536, 2016. https://doi.org/10.3389/fnins.2016.00536 .
doi: 10.3389/fnins.2016.00536
pmcid: 5112261
Martins, R. N., V. Villemagne, H. R. Sohrabi, et al. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL and DIAN cohort studies. J. Alzheimer Dis. 62(3):965–992, 2018. https://doi.org/10.3233/jad-171145 .
doi: 10.3233/jad-171145
Thal, L. J., K. Kantarci, E. M. Reiman, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20(1):6–15, 2006. https://doi.org/10.1097/01.wad.0000191420.61260.a8 .
doi: 10.1097/01.wad.0000191420.61260.a8
pmcid: 1820855
Albert, M. S., S. T. Dekosky, D. Dickson, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dement. 7(3):270–279, 2011. https://doi.org/10.1016/j.jalz.2011.03.008 .
doi: 10.1016/j.jalz.2011.03.008
Granholm, E. L., M. S. Panizzon, J. A. Elman, et al. Pupillary responses as a biomarker of early risk for Alzheimer’s disease. J Alzheimers Dis. 56(4):1419–1428, 2017. https://doi.org/10.3233/JAD-161078 .
doi: 10.3233/JAD-161078
pmcid: 5808562
Tian, T., B. Zhang, Y. Jia, and Z. Li. Promise and challenge: the lens model as a biomarker for early diagnosis of Alzheimer’s disease. Dis. Mark. 2014:826503, 2014. https://doi.org/10.1155/2014/826503 .
doi: 10.1155/2014/826503
Ornek, N., E. Dag, and K. Ornek. Corneal sensitivity and tear function in neurodegenerative diseases. Curr. Eye Res. 40(4):423–428, 2015. https://doi.org/10.3109/02713683.2014.930154 .
doi: 10.3109/02713683.2014.930154
Chaitanuwong, P., S. Jariyakosol, S. Apinyawasisuk, et al. Changes in ocular biomarkers from normal cognitive aging to Alzheimer’s disease: a pilot study. Eye Brain. 15:15–23, 2023. https://doi.org/10.2147/EB.S391608 .
doi: 10.2147/EB.S391608
pmcid: 9986468
Rehan, S., N. Giroud, F. Al-Yawer, W. Wittich, and N. Phillips. Visual performance and cortical atrophy in vision-related brain regions differ between older adults with (or at risk for) Alzheimer’s disease. J. Alzheimer Dis. 83(3):1125–1148, 2021. https://doi.org/10.3233/JAD-201521 .
doi: 10.3233/JAD-201521
Koronyo-Hamaoui, M., Y. Koronyo, A. V. Ljubimov, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 54:S204–S217, 2011. https://doi.org/10.1016/j.neuroimage.2010.06.020 .
doi: 10.1016/j.neuroimage.2010.06.020
Klaver, C. C., A. Ott, A. Hofman, J. J. Assink, M. M. Breteler, and P. T. de Jong. Is age-related maculopathy associated with Alzheimer’s Disease? The Rotterdam study. Am J Epidemiol. 150(9):963–968, 1999. https://doi.org/10.1093/oxfordjournals.aje.a010105 .
doi: 10.1093/oxfordjournals.aje.a010105
Tsai, C. S. Optic nerve head and nerve fiber layer in Alzheimer’s disease. Arch. Ophthalmol. 109(2):199, 1991. https://doi.org/10.1001/archopht.1991.01080020045040 .
doi: 10.1001/archopht.1991.01080020045040
Lu, Y., Z. Li, X. Zhang, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci. Lett. 480(1):69–72, 2010. https://doi.org/10.1016/j.neulet.2010.06.006 .
doi: 10.1016/j.neulet.2010.06.006
Vij, R., and S. Arora. A systematic survey of advances in retinal imaging modalities for Alzheimer’s disease diagnosis. Metab. Brain Dis. 37(7):2213–2243, 2022. https://doi.org/10.1007/s11011-022-00927-4 .
doi: 10.1007/s11011-022-00927-4
Danesh-Meyer, H. V., H. Birch, J. Y. Ku, S. Carroll, and G. Gamble. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 67(10):1852–1854, 2006. https://doi.org/10.1212/01.wnl.0000244490.07925.8b .
doi: 10.1212/01.wnl.0000244490.07925.8b
Kurna, S. A., G. Akar, A. Altun, Y. Agirman, E. Gozke, and T. Sengor. Confocal scanning laser tomography of the optic nerve head on the patients with Alzheimer’s disease compared to glaucoma and control. Int. Ophthalmol. 34(6):1203–1211, 2014. https://doi.org/10.1007/s10792-014-0004-z .
doi: 10.1007/s10792-014-0004-z
Koronyo, Y., D. Biggs, E. Barron, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017. https://doi.org/10.1172/jci.insight.93621 .
doi: 10.1172/jci.insight.93621
pmcid: 5621887
Jentsch, S., D. Schweitzer, K. U. Schmidtke, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol. 93(4):e241–e247, 2015. https://doi.org/10.1111/aos.12609 .
doi: 10.1111/aos.12609
Sadda, S. R., E. Borrelli, W. Fan, et al. A pilot study of fluorescence lifetime imaging ophthalmoscopy in preclinical Alzheimer’s disease. Eye (Lond). 33(8):1271–1279, 2019. https://doi.org/10.1038/s41433-019-0406-2 .
doi: 10.1038/s41433-019-0406-2
pmcid: 7005755
Colligris, P., M. J. Perez de Lara, B. Colligris, and J. Pintor. Ocular manifestations of Alzheimer’s and other neurodegenerative diseases: the prospect of the eye as a tool for the early diagnosis of Alzheimer’s disease. J. Ophthalmol. 2018:8538573, 2018. https://doi.org/10.1155/2018/8538573 .
doi: 10.1155/2018/8538573
pmcid: 6091327
Budenz, D. L., D. R. Anderson, R. Varma, et al. Determinants of normal retinal nerve fiber layer thickness measured by stratus OCT. Ophthalmology. 114(6):1046–1052, 2007. https://doi.org/10.1016/j.ophtha.2006.08.046 .
doi: 10.1016/j.ophtha.2006.08.046
Cunha, J. P., R. Proenca, A. Dias-Santos, et al. OCT in Alzheimer’s disease: thinning of the RNFL and superior hemiretina. Graefes. Arch. Clin. Exp. Ophthalmol. 255(9):1827–1835, 2017. https://doi.org/10.1007/s00417-017-3715-9 .
doi: 10.1007/s00417-017-3715-9
Berisha, F., G. T. Feke, C. L. Trempe, J. W. McMeel, and C. L. Schepens. Retinal abnormalities in early Alzheimer’s disease. Invest. Opthalmol. Vis. Sci. 48(5):2285, 2007. https://doi.org/10.1167/iovs.06-1029 .
doi: 10.1167/iovs.06-1029
Sánchez, D., M. Castilla-Marti, O. Rodríguez-Gómez, et al. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease. Sci. Rep. 2018. https://doi.org/10.1038/s41598-018-34577-3 .
doi: 10.1038/s41598-018-34577-3
pmcid: 6288161
Den Haan, J., L. Csinscik, T. Parker, et al. Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease. Alzheimer Res. Ther. 2019. https://doi.org/10.1186/s13195-019-0516-x .
doi: 10.1186/s13195-019-0516-x
Zhang, Y. S., N. Zhou, B. M. Knoll, et al. Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer’s disease on optical coherence tomography angiography. PLOS ONE. 14(4):e0214685, 2019. https://doi.org/10.1371/journal.pone.0214685 .
doi: 10.1371/journal.pone.0214685
pmcid: 6445433
Zabel, P., J. J. Kaluzny, M. Wilkosc-Debczynska, et al. Comparison of retinal microvasculature in patients with Alzheimer’s disease and primary open-angle glaucoma by optical coherence tomography angiography. Invest. Ophthalmol. Vis. Sci. 60(10):3447–3455, 2019. https://doi.org/10.1167/iovs.19-27028 .
doi: 10.1167/iovs.19-27028
Salobrar-Garcia, E., C. Mendez-Hernandez, R. Hoz, et al. Ocular vascular changes in mild Alzheimer’s disease patients: foveal avascular zone, choroidal thickness, and ONH hemoglobin analysis. J. Pers. Med. 2020. https://doi.org/10.3390/jpm10040231 .
doi: 10.3390/jpm10040231
pmcid: 7712569
Lopez-de-Eguileta, A., C. Lage, S. Lopez-Garcia, et al. Evaluation of choroidal thickness in prodromal Alzheimer’s disease defined by amyloid PET. PLoS One. 15(9):e0239484, 2020. https://doi.org/10.1371/journal.pone.0239484 .
doi: 10.1371/journal.pone.0239484
pmcid: 7505462
Li, M., R. Li, J. H. Lyu, et al. Relationship between Alzheimer’s disease and retinal choroidal thickness: a cross-sectional study. J. Alzheimers Dis. 80(1):407–419, 2021. https://doi.org/10.3233/JAD-201142 .
doi: 10.3233/JAD-201142
Querques, G., E. Borrelli, R. Sacconi, et al. Functional and morphological changes of the retinal vessels in Alzheimer’s disease and mild cognitive impairment. Sci. Rep. 2019. https://doi.org/10.1038/s41598-018-37271-6 .
doi: 10.1038/s41598-018-37271-6
pmcid: 6863896
Yoon, S. P., D. S. Grewal, A. C. Thompson, et al. Retinal microvascular and neurodegenerative changes in Alzheimer’s disease and mild cognitive impairment compared with control participants. Ophthalmol. Retina. 3(6):489–499, 2019. https://doi.org/10.1016/j.oret.2019.02.002 .
doi: 10.1016/j.oret.2019.02.002
pmcid: 6586560
Song, A., N. Johnson, A. Ayala, and A. C. Thompson. Optical coherence tomography in patients with Alzheimer’s disease: what can it tell us? Eye Brain. 13:1–20, 2021. https://doi.org/10.2147/eb.s235238 .
doi: 10.2147/eb.s235238
pmcid: 7802785
Krasodomska, K., W. Lubinski, A. Potemkowski, and K. Honczarenko. Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer’s disease. Doc. Ophthalmol. 121(2):111–121, 2010. https://doi.org/10.1007/s10633-010-9238-x .
doi: 10.1007/s10633-010-9238-x
pmcid: 2941083
Liao, C., J. Xu, Y. Chen, and N. Y. Ip. Retinal dysfunction in Alzheimer’s disease and implications for biomarkers. Biomolecules. 2021. https://doi.org/10.3390/biom11081215 .
doi: 10.3390/biom11081215
pmcid: 8698649
Samra, K., A. M. MacDougall, A. Bouzigues, et al. Genetic forms of primary progressive aphasia within the GENetic frontotemporal dementia initiative (GENFI) cohort: comparison with sporadic primary progressive aphasia. Brain Commun. 5(2):fcad036, 2023. https://doi.org/10.1093/braincomms/fcad036 .
doi: 10.1093/braincomms/fcad036
pmcid: 10019761
Meeter, L. H., L. D. Kaat, J. D. Rohrer, and J. C. Van Swieten. Imaging and fluid biomarkers in frontotemporal dementia. Nat. Rev. Neurol. 13(7):406–419, 2017. https://doi.org/10.1038/nrneurol.2017.75 .
doi: 10.1038/nrneurol.2017.75
Moinuddin, O., N. S. Khandwala, K. Z. Young, et al. Role of optical coherence tomography in identifying retinal biomarkers in frontotemporal dementia: a review. Neurol. Clin. Pract. 11(4):e516–e523, 2021. https://doi.org/10.1212/CPJ.0000000000001041 .
doi: 10.1212/CPJ.0000000000001041
pmcid: 8382404
Hutchings, R., R. Palermo, J. Bruggemann, J. R. Hodges, O. Piguet, and F. Kumfor. Looking but not seeing: increased eye fixations in behavioural-variant frontotemporal dementia. Cortex. 103:71–81, 2018. https://doi.org/10.1016/j.cortex.2018.02.011 .
doi: 10.1016/j.cortex.2018.02.011
Moon, S. Y., B. H. Lee, S. W. Seo, S. J. Kang, and D. L. Na. Slow vertical saccades in the frontotemporal dementia with motor neuron disease. J. Neurol. 255(9):1337–1343, 2008. https://doi.org/10.1007/s00415-008-0890-y .
doi: 10.1007/s00415-008-0890-y
Ferrari, L., S. C. Huang, G. Magnani, A. Ambrosi, G. Comi, and L. Leocani. Optical coherence tomography reveals retinal neuroaxonal thinning in frontotemporal dementia as in Alzheimer’s disease. J. Alzheimers Dis. 56(3):1101–1107, 2017. https://doi.org/10.3233/JAD-160886 .
doi: 10.3233/JAD-160886
Kim, B. J., D. J. Irwin, D. Song, et al. Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology. 89(15):1604–1611, 2017. https://doi.org/10.1212/wnl.0000000000004500 .
doi: 10.1212/wnl.0000000000004500
pmcid: 5634666
Kim, B. J., M. Grossman, D. Song, et al. Persistent and progressive outer retina thinning in frontotemporal degeneration. Front. Neurosci. 13:298, 2019. https://doi.org/10.3389/fnins.2019.00298 .
doi: 10.3389/fnins.2019.00298
pmcid: 6459211
Cofreces, P., S. D. Ofman, J. A. Estay, and P. D. Hermida. Enfermedad de Parkinson: una actualizacion bibliografica de los aspectos psicosociales. Rev. Fac. Cien. Med. Univ. Nac. Cordoba. 79(2):181–187, 2022. https://doi.org/10.31053/1853.0605.v79.n2.33610 .
doi: 10.31053/1853.0605.v79.n2.33610
pmcid: 9426325
Khan, M. A., N. Haider, T. Singh, et al. Promising biomarkers and therapeutic targets for the management of Parkinson’s disease: recent advancements and contemporary research. Metab Brain Dis. 38(3):873–919, 2023. https://doi.org/10.1007/s11011-023-01180-z .
doi: 10.1007/s11011-023-01180-z
Rekik, A., S. Mrabet, A. Nasri, et al. Eye movement study in essential tremor patients and its clinical correlates. J. Neural. Transm. (Vienna). 130(4):537–548, 2023. https://doi.org/10.1007/s00702-023-02614-9 .
doi: 10.1007/s00702-023-02614-9
Davidsdottir, S., A. Cronin-Golomb, and A. Lee. Visual and spatial symptoms in Parkinson’s disease. Vision Res. 45(10):1285–1296, 2005. https://doi.org/10.1016/j.visres.2004.11.006 .
doi: 10.1016/j.visres.2004.11.006
Huang, J., Y. Li, J. Xiao, et al. Combination of multifocal electroretinogram and spectral-domain OCT can increase diagnostic efficacy of Parkinson’s disease. Parkinson’s Dis. 2018:1–7, 2018. https://doi.org/10.1155/2018/4163239 .
doi: 10.1155/2018/4163239
Unlu, M., D. Gulmez Sevim, M. Gultekin, and C. Karaca. Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson’s disease. Neurol. Sci. 39(3):533–541, 2018. https://doi.org/10.1007/s10072-018-3244-2 .
doi: 10.1007/s10072-018-3244-2
Stemplewitz, B., M. Keseru, D. Bittersohl, et al. Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson’s disease. Acta Ophthalmol. 93(8):e672–e677, 2015. https://doi.org/10.1111/aos.12764 .
doi: 10.1111/aos.12764
Chorostecki, J., N. Seraji-Bozorgzad, A. Shah, et al. Characterization of retinal architecture in Parkinson’s disease. J. Neurol. Sci. 355(1–2):44–48, 2015. https://doi.org/10.1016/j.jns.2015.05.007 .
doi: 10.1016/j.jns.2015.05.007
Devos, D., M. Tir, C. A. Maurage, et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology. 65(7):1107–1110, 2005. https://doi.org/10.1212/01.wnl.0000178896.44905.33 .
doi: 10.1212/01.wnl.0000178896.44905.33
Alves, J. N., B. U. Westner, A. Højlund, R. S. Weil, and S. S. Dalal. Structural and functional changes in the retina in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2023. https://doi.org/10.1136/jnnp-2022-329342 .
doi: 10.1136/jnnp-2022-329342
Kaur, M., R. Saxena, D. Singh, M. Behari, P. Sharma, and V. Menon. Correlation between structural and functional retinal changes in Parkinson disease. J Neuroophthalmol. 35(3):254–258, 2015. https://doi.org/10.1097/WNO.0000000000000240 .
doi: 10.1097/WNO.0000000000000240
Sari, E. S., R. Koc, A. Yazici, G. Sahin, and S. S. Ermis. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J Neuroophthalmol. 35(2):117–121, 2015. https://doi.org/10.1097/WNO.0000000000000203 .
doi: 10.1097/WNO.0000000000000203
Satue, M., J. Obis, R. Alarcia, et al. Retinal and choroidal changes in patients with Parkinson’s disease detected by swept-source optical coherence tomography. Curr. Eye Res. 43(1):109–115, 2018. https://doi.org/10.1080/02713683.2017.1370116 .
doi: 10.1080/02713683.2017.1370116
Obis, J., M. Satue, R. Alarcia, L. E. Pablo, and E. Garcia-Martin. Actualizacion sobre alteraciones de funcion visual y espesores coriorretinianos en la enfermedad de Parkinson. Arch. Soc. Esp. Oftalmol. (Engl Ed). 93(5):231–238, 2018. https://doi.org/10.1016/j.oftal.2018.01.004 .
doi: 10.1016/j.oftal.2018.01.004
Brown, G. L., M. L. Camacci, S. D. Kim, et al. Choroidal thickness correlates with clinical and imaging metrics of Parkinson’s disease: a pilot study. J. Parkinsons Dis. 11(4):1857–1868, 2021. https://doi.org/10.3233/JPD-212676 .
doi: 10.3233/JPD-212676
pmcid: 8530855
Moschos, M. M., and I. P. Chatziralli. Evaluation of choroidal and retinal thickness changes in Parkinson’s disease using spectral domain optical coherence tomography. Semin. Ophthalmol. 33(4):494–497, 2018. https://doi.org/10.1080/08820538.2017.1307423 .
doi: 10.1080/08820538.2017.1307423
Eraslan, M., E. Cerman, S. Yildiz Balci, et al. The choroid and lamina cribrosa is affected in patients with Parkinson’s disease: enhanced depth imaging optical coherence tomography study. Acta Ophthalmol. 94(1):e68-75, 2016. https://doi.org/10.1111/aos.12809 .
doi: 10.1111/aos.12809
Kamata, Y., N. Hara, T. Satou, T. Niida, and K. Mukuno. Investigation of the pathophysiology of the retina and choroid in Parkinson’s disease by optical coherence tomography. Int. Ophthalmol. 42(5):1437–1445, 2022. https://doi.org/10.1007/s10792-021-02133-0 .
doi: 10.1007/s10792-021-02133-0
Zhang, Y., L. Yang, Y. Gao, et al. Choroid and choriocapillaris changes in early-stage Parkinson’s disease: a swept-source optical coherence tomography angiography-based cross-sectional study. Alzheimers Res. Ther. 14(1):116, 2022. https://doi.org/10.1186/s13195-022-01054-z .
doi: 10.1186/s13195-022-01054-z
pmcid: 9404633
Garcia-Martin, E., L. E. Pablo, M. P. Bambo, et al. Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson’s disease. PLoS One. 12(5):e0177163, 2017. https://doi.org/10.1371/journal.pone.0177163 .
doi: 10.1371/journal.pone.0177163
pmcid: 5433703
Garcia-Martin, E., D. Rodriguez-Mena, M. Satue, et al. Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity. Invest. Ophthalmol. Vis. Sci. 55(2):696–705, 2014. https://doi.org/10.1167/iovs.13-13062 .
doi: 10.1167/iovs.13-13062
Moschos, M. M., G. Tagaris, I. Markopoulos, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur. J. Ophthalmol. 21(1):24–29, 2011. https://doi.org/10.5301/ejo.2010.1318 .
doi: 10.5301/ejo.2010.1318
Kupersmith, M. J., E. Shakin, I. M. Siegel, and A. Lieberman. Visual system abnormalities in patients with Parkinson’s disease. Arch. Neurol. 39(5):284–286, 1982. https://doi.org/10.1001/archneur.1982.00510170026007 .
doi: 10.1001/archneur.1982.00510170026007
Batum, M., A. K. Ak, M. S. Ari, H. Mayali, E. Kurt, and D. Selcuki. Evaluation of the visual system with visual evoked potential and optical coherence tomography in patients with idiopathic Parkinson’s disease and with multiple system atrophy. Doc. Ophthalmol. 145(2):99–112, 2022. https://doi.org/10.1007/s10633-022-09887-7 .
doi: 10.1007/s10633-022-09887-7
Carrarini, C., M. Russo, G. Pagliaccio, et al. Visual evoked potential abnormalities in dementia with Lewy bodies. Neurophysiol. Clin. 51(5):425–431, 2021. https://doi.org/10.1016/j.neucli.2021.02.003 .
doi: 10.1016/j.neucli.2021.02.003
Zhou, M., L. Wu, Q. Hu, et al. Visual impairments are associated with retinal microvascular density in patients with Parkinson’s disease. Front. Neurosci. 15:718820, 2021. https://doi.org/10.3389/fnins.2021.718820 .
doi: 10.3389/fnins.2021.718820
pmcid: 8406760
Tuncer, Z., G. Dereli Can, H. Donmez Keklikoglu, F. A. Eren, F. Yulek, and O. Deniz. The Relationship between visual-evoked potential and optic coherence tomography and clinical findings in Parkinson patients. Parkinsons Dis. 2023:7739944, 2023. https://doi.org/10.1155/2023/7739944 .
doi: 10.1155/2023/7739944
pmcid: 9981293
Witkovsky, P. Dopamine and retinal function. Doc. Ophthalmol. 108(1):17–39, 2004. https://doi.org/10.1023/b:doop.0000019487.88486.0a .
doi: 10.1023/b:doop.0000019487.88486.0a
Ikeda, H., G. M. Head, and C. J. Ellis. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson’s disease and a follow up study. Vision Res. 34(19):2629–2638, 1994. https://doi.org/10.1016/0042-6989(94)90248-8 .
doi: 10.1016/0042-6989(94)90248-8
Gottlob, I., H. Weghaupt, C. Vass, and E. Auff. Effect of levodopa on the human pattern electroretinogram and pattern visual evoked potentials. Graefes. Arch. Clin. Exp. Ophthalmol. 227(5):421–427, 1989. https://doi.org/10.1007/BF02172892 .
doi: 10.1007/BF02172892
Christou, E. E., S. Konitsiotis, K. Pamporis, et al. Inner retinal layers’ alterations of the microvasculature in early stages of Parkinson’s disease: a cross sectional study. Int. Ophthalmol. 2023. https://doi.org/10.1007/s10792-023-02653-x .
doi: 10.1007/s10792-023-02653-x
Christou, E. E., I. Asproudis, C. Asproudis, A. Giannakis, M. Stefaniotou, and S. Konitsiotis. Macular microcirculation characteristics in Parkinson’s disease evaluated by OCT-angiography: a literature review. Semin. Ophthalmol. 37(3):399–407, 2022. https://doi.org/10.1080/08820538.2021.1987482 .
doi: 10.1080/08820538.2021.1987482
Kwapong, W. R., H. Ye, C. Peng, et al. Retinal microvascular impairment in the early stages of Parkinson’s disease. Invest. Ophthalmol. Vis. Sci. 59(10):4115–4122, 2018. https://doi.org/10.1167/iovs.17-23230 .
doi: 10.1167/iovs.17-23230
McGrath, M. S., R. Zhang, P. M. Bracci, A. Azhir, and B. D. Forrest. Regulation of the innate immune system as a therapeutic approach to supporting respiratory function in ALS. Cells. 2023. https://doi.org/10.3390/cells12071031 .
doi: 10.3390/cells12071031
pmcid: 10093136
Verber, N., and P. J. Shaw. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr. Opin. Neurol. 33(5):662–668, 2020. https://doi.org/10.1097/wco.0000000000000854 .
doi: 10.1097/wco.0000000000000854
Mitsumoto, H., and T. Saito. A prognostic biomarker in amyotrophic lateral sclerosis. Rinsho Shinkeigaku. 58(12):729–736, 2018. https://doi.org/10.5692/clinicalneurol.cn-001220 .
doi: 10.5692/clinicalneurol.cn-001220
Youn, C. E., C. Lu, J. Cauchi, D. MacGowan, R. Morgenstern, and S. Scelsa. Oculomotor dysfunction in motor neuron disease. J. Neuromuscul. Dis. 2023. https://doi.org/10.3233/JND-221579 .
doi: 10.3233/JND-221579
Ringelstein, M., P. Albrecht, M. Südmeyer, et al. Subtle retinal pathology in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 1(4):290–297, 2014. https://doi.org/10.1002/acn3.46 .
doi: 10.1002/acn3.46
pmcid: 4292746
Mohanty, B., A. K. Misra, S. Kumar, et al. Retinal nerve fiber layer thinning found in amyotrophic lateral sclerosis—Correlation with disease duration and severity. Indian J. Ophthalmol. 71(2):369–378, 2023. https://doi.org/10.4103/ijo.IJO_1870_22 .
doi: 10.4103/ijo.IJO_1870_22
pmcid: 10228946
Zhang, Y., X. Liu, J. Fu, et al. Selective and inverse U-shaped curve alteration of the retinal nerve in amyotrophic lateral sclerosis: a potential mirror of the disease. Front. Aging Neurosci. 13:783431, 2021. https://doi.org/10.3389/fnagi.2021.783431 .
doi: 10.3389/fnagi.2021.783431
Hubers, A., H. P. Muller, J. Dreyhaupt, et al. Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. J. Neural. Transm. (Vienna). 123(3):281–287, 2016. https://doi.org/10.1007/s00702-015-1483-4 .
doi: 10.1007/s00702-015-1483-4
Rohani, M., A. Meysamie, B. Zamani, M. M. Sowlat, and F. H. Akhoundi. Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression. J. Neurol. 265(7):1557–1562, 2018. https://doi.org/10.1007/s00415-018-8863-2 .
doi: 10.1007/s00415-018-8863-2
Nepal, G., S. Kharel, M. A. Coghlan, et al. Amyotrophic lateral sclerosis and retinal changes in optical coherence tomography: a systematic review and meta-analysis. Brain Behav. 12(9):e2741, 2022. https://doi.org/10.1002/brb3.2741 .
doi: 10.1002/brb3.2741
pmcid: 9480919
Yap, T. E., S. I. Balendra, M. T. Almonte, and M. F. Cordeiro. Retinal correlates of neurological disorders. Ther. Adv. Chronic Dis. 10:2040622319882205, 2019. https://doi.org/10.1177/2040622319882205 .
doi: 10.1177/2040622319882205
pmcid: 6887800
Abdelhak, A., A. Hübers, K. Böhm, A. C. Ludolph, J. Kassubek, and E. H. Pinkhardt. In vivo assessment of retinal vessel pathology in amyotrophic lateral sclerosis. J. Neurol. 265(4):949–953, 2018. https://doi.org/10.1007/s00415-018-8787-x .
doi: 10.1007/s00415-018-8787-x
Kolde, G., R. Bachus, and A. C. Ludolph. Skin involvement in amyotrophic lateral sclerosis. Lancet. 347(9010):1226–1227, 1996. https://doi.org/10.1016/s0140-6736(96)90737-0 .
doi: 10.1016/s0140-6736(96)90737-0
Cennamo, G., D. Montorio, F. P. Ausiello, et al. Correlation between retinal vascularization and disease aggressiveness in amyotrophic lateral sclerosis. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10102390 .
doi: 10.3390/biomedicines10102390
pmcid: 9598742
Simonett, J. M., R. Huang, N. Siddique, et al. Macular sub-layer thinning and association with pulmonary function tests in Amyotrophic Lateral Sclerosis. Sci. Rep. 6(1):29187, 2016. https://doi.org/10.1038/srep29187 .
doi: 10.1038/srep29187
pmcid: 4935870
Imarisio, S., J. Carmichael, V. Korolchuk, et al. Huntington’s disease: from pathology and genetics to potential therapies. Biochem. J. 412(2):191–209, 2008. https://doi.org/10.1042/BJ20071619 .
doi: 10.1042/BJ20071619
Zeun, P., R. I. Scahill, S. J. Tabrizi, and E. J. Wild. Fluid and imaging biomarkers for Huntington’s disease. Mol. Cell Neurosci. 97:67–80, 2019. https://doi.org/10.1016/j.mcn.2019.02.004 .
doi: 10.1016/j.mcn.2019.02.004
Knapp, J., D. A. VanNasdale, K. Ramsey, and J. Racine. Retinal dysfunction in a presymptomatic patient with Huntington’s disease. Doc. Ophthalmol. 136(3):213–221, 2018. https://doi.org/10.1007/s10633-018-9632-3 .
doi: 10.1007/s10633-018-9632-3
Amini, E., M. Moghaddasi, S. A. H. Habibi, et al. Huntington’s disease and neurovascular structure of retina. Neurol. Sci. 43(10):5933–5941, 2022. https://doi.org/10.1007/s10072-022-06232-3 .
doi: 10.1007/s10072-022-06232-3
Gatto, E., V. Parisi, G. Persi, et al. Optical coherence tomography (OCT) study in Argentinean Huntington’s disease patients. Int. J. Neurosci. 128(12):1157–1162, 2018. https://doi.org/10.1080/00207454.2018.1489807 .
doi: 10.1080/00207454.2018.1489807
Murueta-Goyena, A., R. Del Pino, M. Acera, et al. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease. J. Neurol. 2023. https://doi.org/10.1007/s00415-023-11720-3 .
doi: 10.1007/s00415-023-11720-3
pmcid: 10345164
Kersten, H. M., H. V. Danesh-Meyer, D. H. Kilfoyle, and R. H. Roxburgh. Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression. J. Neurol. 262(11):2457–2465, 2015. https://doi.org/10.1007/s00415-015-7869-2 .
doi: 10.1007/s00415-015-7869-2
Schmid, R. D., J. Remlinger, M. Abegg, et al. No optical coherence tomography changes in premanifest Huntington’s disease mutation carriers far from disease onset. Brain Behav. 12(6):e2592, 2022. https://doi.org/10.1002/brb3.2592 .
doi: 10.1002/brb3.2592
pmcid: 9226796
Andrade, C., J. Beato, A. Monteiro, et al. Spectral-domain optical coherence tomography as a potential biomarker in Huntington’s disease. Mov. Disord. 31(3):377–383, 2016. https://doi.org/10.1002/mds.26486 .
doi: 10.1002/mds.26486
Dusek, P., A. Kopal, M. Brichova, et al. Is retina affected in Huntington’s disease? Is optical coherence tomography a good biomarker? PLoS One. 18(2):e0282175, 2023. https://doi.org/10.1371/journal.pone.0282175 .
doi: 10.1371/journal.pone.0282175
pmcid: 9955964
Di Maio, L. G., D. Montorio, S. Peluso, et al. Optical coherence tomography angiography findings in Huntington’s disease. Neurol. Sci. 42(3):995–1001, 2021. https://doi.org/10.1007/s10072-020-04611-2 .
doi: 10.1007/s10072-020-04611-2
Mazur-Michalek, I., K. Kowalska, D. Zielonka, et al. Structural abnormalities of the optic nerve and retina in huntington’s disease pre-clinical and clinical settings. Int. J. Mol. Sci. 2022. https://doi.org/10.3390/ijms23105450 .
doi: 10.3390/ijms23105450
pmcid: 9141007
Li, M., D. Yasumura, A. A. K. Ma, et al. Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of Huntington disease. PLoS ONE. 8(2):e56026, 2013. https://doi.org/10.1371/journal.pone.0056026 .
doi: 10.1371/journal.pone.0056026
pmcid: 3569418
Helmlinger, D., G. Yvert, S. Picaud, et al. Progressive retinal degeneration and dysfunction in R6 Huntington’s disease mice. Hum. Mol. Genet. 11(26):3351–3359, 2002. https://doi.org/10.1093/hmg/11.26.3351 .
doi: 10.1093/hmg/11.26.3351
Kwon, J. Y., J. H. Yang, J. S. Han, and D. G. Kim. Analysis of the retinal nerve fiber layer thickness in Alzheimer disease and mild cognitive impairment. Korean J. Ophthalmol. 31(6):548–556, 2017. https://doi.org/10.3341/kjo.2016.0118 .
doi: 10.3341/kjo.2016.0118
pmcid: 5726990